Sai Life Sciences is currently trading at Rs. 756.85, up by 27.65 points or 3.79% from its previous closing of Rs. 729.20 on the BSE.
The scrip opened at Rs. 735.00 and has touched a high and low of Rs. 766.55 and Rs. 720.35 respectively. So far 20991905 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 1 has touched a 52 week high of Rs. 808.20 on 26-Dec-2024 and a 52 week low of Rs. 635.30 on 09-Apr-2025.
Last one week high and low of the scrip stood at Rs. 772.60 and Rs. 716.00 respectively. The current market cap of the company is Rs. 15535.19 crore.
The promoters holding in the company stood at 35.17%, while Institutions and Non-Institutions held 25.62% and 39.21% respectively.
Sai Life Sciences has commenced commercial operation of the second phase of the production block with 91 kL of capacity at its Unit IV Bidar facility in Karnataka, India, on June 19, 2025. This is the second and final phase of the overall capacity addition of 195 kL which was under construction at Unit IV Bidar Facility as disclosed in the prospectus.
Accordingly, the combined capacity of Unit IV Bidar Facility will be 640 kL which will be equipped to supply registered starting materials (RSM), intermediates, and active pharmaceutical ingredients (APIs) for both clinical and commercial purposes.
Sai Life Sciences is a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
Sai Life Sciences soars on commencing commercial operations of Unit IV Bidar facility in Karnataka
